'None of this would matter without you': IAF’s Shubhanshu Shukla’s note to wife before space launch Emergency 1975: The Court ...

GLP-1 obesity drug use is rising, but long-term adherence remains low. While one-year persistence has improved in 2024, only ...

Viatris faces downside risk from regulatory challenges, macro headwinds, and muted growth. Click to learn more on why VTRS ...

At least 29% of young adults in Delhi show signs of lung damage in routine CT scans, including bronchiectasis and emphysema, ...

Tata Group first Indian brand over the $30 billion value mark, Eternal joins the top 50 list Harvard liver specialist suggests consuming 4 snacks weekly to reverse fatty liver Amid speculation, ...

Danish pharma giant Novo Nordisk has brought its weight-loss drug Wegovy to India. This follows US company Eli Lilly's launch ...

Weight loss drugs help manage blood sugar levels by mimicking two important hormones GLP-1 (glucagon-like peptide-1) and GIP ...

The Weight Loss Revolution— that’s released on Wednesday provides a detailed insight into these weight management drugs and ...

With obesity and Type 2 diabetes on the rise, India is emerging as a key battleground for global drugmakers developing next-generation therapies targeting metabolic disorders.

COPENHAGEN - Danish drugmaker Novo Nordisk will launch its weight-loss drug Wegovy in India without any supply constraints, a ...

Wegovy, a weekly weight-loss injection by Novo Nordisk, has launched in India. Priced from Rs 17,000/month, it helps users lose up to 20 per cent body weight. But is it safe? Experts answer.

Mumbai: Novo Nordisk, a global healthcare company headquartered in Denmark, has announced the launch of Wegovy (injectable ...